BioInfra (A199730) Stock Overview
Operates as a contract research organization for phase 1 clinical trials. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 2/6 |
A199730 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
BioInfra Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,345.00 |
| 52 Week High | ₩6,330.00 |
| 52 Week Low | ₩2,190.00 |
| Beta | 0.37 |
| 1 Month Change | -24.72% |
| 3 Month Change | -40.48% |
| 1 Year Change | -59.22% |
| 3 Year Change | -85.94% |
| 5 Year Change | n/a |
| Change since IPO | -92.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| A199730 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -1.5% | 5.0% | -3.6% |
| 1Y | -59.2% | -9.5% | 148.4% |
Return vs Industry: A199730 underperformed the KR Life Sciences industry which returned -9.5% over the past year.
Return vs Market: A199730 underperformed the KR Market which returned 148.4% over the past year.
Price Volatility
| A199730 volatility | |
|---|---|
| A199730 Average Weekly Movement | 6.9% |
| Life Sciences Industry Average Movement | 11.2% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in KR Market | 16.5% |
| 10% least volatile stocks in KR Market | 4.9% |
Stable Share Price: A199730 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A199730's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Sangdeuk Lee | www.bioinfrakorea.co.kr |
BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of generic drugs, phase 1 clinical trials for new and improved drugs; and sample analysis services for new drug substances.
BioInfra Co., Ltd. Fundamentals Summary
| A199730 fundamental statistics | |
|---|---|
| Market cap | ₩11.48b |
| Earnings (TTM) | -₩9.89b |
| Revenue (TTM) | ₩23.21b |
Is A199730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A199730 income statement (TTM) | |
|---|---|
| Revenue | ₩23.21b |
| Cost of Revenue | ₩17.91b |
| Gross Profit | ₩5.29b |
| Other Expenses | ₩15.18b |
| Earnings | -₩9.89b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03k |
| Gross Margin | 22.81% |
| Net Profit Margin | -42.60% |
| Debt/Equity Ratio | 101.3% |
How did A199730 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 08:47 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioInfra Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.